EUVIMEDEUVIMED entdecken
Crossref

Real‐world efficacy of single‐agent belantamab mafodotin in relapsed systemic AL amyloidosis

Jahanzaib Khwaja iD, Joshua Bomsztyk iD, Maria Atta, Ceri Bygrave iD, Adam Forbes, Senthil Durairaj, Savio Fernandes, James Taylor, Pamela Paterson, Gillian Brearton, Charles Crawley, Oonagh Sheehy iD und 7 weitere

British Journal of Haematology · 2024-05 · 204 (5) · 1811-1815

DOI: 10.1111/bjh.19286 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 03.01.2024. Verfasst von Jahanzaib Khwaja und 18 weiteren Autor:innen. Beteiligte Einrichtung: University College London Hospital, London, UK. Hauptthemen laut MEDLINE: Immunoglobulin Light-chain Amyloidosis, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Systemic light chain (AL) amyloidosis is a relapsing plasma cell disorder. Therapy is limited, particularly for triple‐class refractory disease. We report the use of belantamab mafodotin, a BCMA‐directed drug–antibody conjugate, for relapsed AL amyloidosis, including patients traditionally excluded from clinical trials. Thirty‐one patients were reviewed, with a median of three prior lines of therapy. The median follow‐up was 12 months (95% CI 4–19), and a median of five doses were delivered. The best haematological overall response rate was 71%, and the complete/very good partial response was 58%. Sixty‐eight percent had keratopathy and improved in all. Belantamab mafodotin has high efficacy and good tolerability in patients with relapsed AL amyloidosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulin Light-chain AmyloidosisAntibodies, Monoclonal, HumanizedHumansMaleFemaleAgedMiddle AgedRecurrenceAged, 80 and overTreatment OutcomeRetrospective StudiesAdult

Stichwörter der Autor:innen

amyloidosisantibody therapyimmunotherapy

Substanzen

belantamab mafodotinAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • University College London Hospital, London, UK.
  • National Amyloidosis Centre, University College London (Royal Free Campus), London, UK.
  • Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
  • University Hospital of Wales, Wales, UK.
  • Royal Cornwall Hospital NHS Trust, Truro, UK.
  • Hull University Teaching Hospitals NHS Trust, Hull, UK.

ORCID-Profile: Jahanzaib Khwaja, Joshua Bomsztyk, Ceri Bygrave, Oonagh Sheehy

Zitieren

APA

Khwaja, J., Bomsztyk, J., Atta, M., Bygrave, C., Forbes, A., Durairaj, S., Fernandes, S., Taylor, J., Paterson, P., Brearton, G., Crawley, C., Sheehy, O., Brown, R., Soutar, R., Garg, M., Rydzewski, A., Jamroziak, K., Mahmood, S., & Wechalekar, A. D. (2024). Real‐world efficacy of single‐agent belantamab mafodotin in relapsed systemic AL amyloidosis. British Journal of Haematology, 204(5), 1811-1815. https://doi.org/10.1111/bjh.19286

Vancouver

Khwaja J, Bomsztyk J, Atta M, Bygrave C, Forbes A, Durairaj S, et al. Real‐world efficacy of single‐agent belantamab mafodotin in relapsed systemic AL amyloidosis. British Journal of Haematology. 2024;204(5):1811-1815. doi:10.1111/bjh.19286

BibTeX
@article{Khwaja2024,
  author = {Khwaja, Jahanzaib and Bomsztyk, Joshua and Atta, Maria and Bygrave, Ceri and Forbes, Adam and Durairaj, Senthil and Fernandes, Savio and Taylor, James and Paterson, Pamela and Brearton, Gillian and Crawley, Charles and Sheehy, Oonagh and Brown, Rachel and Soutar, Richard and Garg, Mamta and Rydzewski, Andrzej and Jamroziak, Krzysztof and Mahmood, Shameem and Wechalekar, Ashutosh D},
  title = {Real‐world efficacy of single‐agent belantamab mafodotin in relapsed systemic AL amyloidosis},
  journal = {British Journal of Haematology},
  year = {2024},
  volume = {204},
  number = {5},
  pages = {1811--1815},
  doi = {10.1111/bjh.19286}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche